# A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

> **NCT02491528** · PHASE3 · COMPLETED · sponsor: **Tonghua Dongbao Pharmaceutical Co.,Ltd** · enrollment: 563 (actual)

## Conditions studied

- Diabetes

## Interventions

- **BIOLOGICAL:** insulin Aspart injection
- **BIOLOGICAL:** insulin Aspart injection (NovoRapid)

## Key facts

- **NCT ID:** NCT02491528
- **Lead sponsor:** Tonghua Dongbao Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-19
- **Primary completion:** 2016-08-12
- **Final completion:** 2016-08-12
- **Target enrollment:** 563 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491528, "A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02491528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*